Related Experiment Videos
[Bendazac hepatotoxicity: analysis of 16 cases]
J M Prieto de Paula1, E Rodríguez Rodríguez, V Villamandos Nicás
1Servicio de Medicina Interna, Hospital Santos Reyes, Aranda de Duero, Burgos.
Revista Clinica Espanola
|June 1, 1995
Summary
Non-steroid anti-inflammatory drugs (NSAIDs) can cause liver damage, especially in older adults. Bendazac, an NSAID used for cataracts, was studied in 16 patients, revealing a need for careful NSAID prescription.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Non-steroid anti-inflammatory drugs (NSAIDs) are frequently associated with drug-induced liver injury.
- Hepatic lesions from NSAIDs are a significant cause of morbidity, particularly in elderly populations.
- The clinical presentation of NSAID-induced liver disease is diverse, often marked by elevated serum transaminases.
Purpose of the Study:
- To investigate the spectrum of liver disease associated with bendazac, a specific NSAID.
- To analyze clinical data from patients experiencing hepatic events during bendazac therapy.
- To emphasize the importance of judicious NSAID selection in clinical practice.
Main Methods:
- Retrospective study of 16 patients with hepatic lesions attributed to bendazac.
- Analysis of clinical data from a cohort of 112 patients undergoing bendazac treatment for cataracts.
- Review of the clinical presentation and outcomes of NSAID-induced liver injury.
Main Results:
- Bendazac was identified as the causative agent in 16 cases of hepatic lesions.
- Elevated serum transaminase levels were a predominant finding in affected patients.
- The study cohort included patients treated with bendazac for cataracts.
Conclusions:
- Bendazac can induce hepatic lesions, contributing to the spectrum of NSAID-related liver disease.
- Careful consideration of patient selection and indications for NSAID use is crucial.
- Monitoring for liver enzyme abnormalities is recommended during NSAID therapy, particularly with bendazac.